Breathlessness during exercise in COPD: How do the drugs work?

Thorax

Volumn 59, Issue 6, 2004, Pages 455-457

  Calverley, P M A ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; IPRATROPIUM BROMIDE; OXYGEN; SALMETEROL; BRONCHODILATING AGENT; DRUG DERIVATIVE; SALBUTAMOL;

BREATHING MUSCLE; BREATHING RATE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIAPHRAGM; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SCREENING; DYSPNEA; EDITORIAL; ENERGY EXPENDITURE; EXERCISE; FATIGUE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG CAPACITY; LUNG FUNCTION; LUNG PERFUSION; LUNG VENTILATION; LUNG VOLUME; METHODOLOGY; OXYGEN CONSUMPTION; PATIENT; PRIORITY JOURNAL; QUALITY OF LIFE; SMOOTH MUSCLE RELAXATION; SPIROMETRY; WORKLOAD; NOTE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALBUTEROL; BRONCHODILATOR AGENTS; DYSPNEA; EXERCISE; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 2942655403     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2004.023150     Document Type: Editorial

References (28)

1. Rennard SI, Decramer M, Calverley PMA, et al. The impact of COPD in North America and Europe: the patient's perspective of the confronting COPD international survey. Eur Respir J 2002;20:1-7.
2. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001;56:880-7.
3. Spiro SG, Hahn HL, Edwards RH, et al. An analysis of the physiological strain of submaximal exercise in patients with chronic obstructive bronchitis. Thorax 1975;30:415-25.
4. McGavin CR, Gupta SP, McHardy GJ. Twelve-minute walking test for assessing disability in chronic bronchitis. BMJ 1976;1:822-3.
5. Agusti AG, Barbera JA, Roca J, et al. Hypoxic pulmonary vasoconstriction and gas exchange during exercise in chronic obstructive pulmonary disease. Chest 1990;97:268-75.
6. Casaburi R, Patessio A, Ioli F, et al. Reductions in exercise lactic acidosis and ventilation as a result of exercise training in patients with obstructive lung disease. Am Rev Respir Dis 1991;143:9-18.
7. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung hyperinflation. Am Rev Respir Dis 1993;148:1351-7.
8. O'Donnell DE, D'Arsigny C, Fitzpatrick M, et al. Exercise hypercapnia in advanced chronic obstructive pulmonary disease: the role of lung hyperinflation. Am J Respir Crit Care Med 2002;166:663-8.
9. Aliverti A, Stevenson N, Dellaca RL, et al. Regional chest wall volumes during exercise in chronic obstructive pulmonary disease. Thorax 2004;59:210-6.
10. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med 1999;159:321-40.
11. O'Donnell DE, Bertley JC, Chau LK, et al. Qualitative aspects of exertional breathlessness in chronic airflow limitation: pathophysiologic mechanisms. Am J Respir Critl Care Med 1997;155:109-15.
12. McKenzie DK, Bellemare F. Respiratory muscle fatigue. Advan Exp Med Biol 1995;384:401-14.
13. Mador MJ, Kufel TJ, Pineda LA, et al. Diaphragmatic fatigue and high-intensity exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161:118-23.
14. Calverley PM, Burge PS, Spencer S, et al. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003;58:659-64.
15. Burge PS, Calverley PM, Jones PW, et al. Prednisolone response in patients with chronic obstructive pulmonary disease: results from the ISOLDE study. Thorax 2003;58:654-8.
16. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992;5:659-64.
17. Leitch AG, Hopkin JM, Ellis DA, et al. The effect of aerosol ipratropium bromide and salbutamol on exercise tolerance in chronic bronchitis. Thorax 1978;33:711-3.
18. Spence DP, Hay JG, Carter J, et al. Oxygen desaturation and breathlessness during corridor walking in chronic obstructive pulmonary disease: effect of oxitropium bromide. Thorax 1993;48:1145-50.
19. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999;160:542-9.
20. Belman MJ, Botnick WC, Shin JW. Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1996;153:967-75.
21. Man W D-C, Mustfa N, Nikoletou D, et al. Effect of salmeterol on respiratory muscle activity during exercise in poorly reversible COPD. Thorax 2004;59:471-6.
22. Duranti R, Misuri G, Gorini M, et al. Mechanical loading and control of breathing in patients with severe chronic obstructive pulmonary disease. Thorax 1995;50:127-33.
23. Gorini M, Misuri G, Corrado A, et al. Breathing pattern and carbon dioxide retention in severe chronic obstructive pulmonary disease. Thorax 1996;51:677-83.
24. Hadcroft J, Calverley PM. Alternative methods for assessing bronchodilator reversibility in chronic obstructive pulmonary disease. Thorax 2001;56:713-20.
25. Kyroussis D, Polkey MI, Hamnegard CH, et al. Respiratory muscle activity in patients with COPD walking to exhaustion with and without pressure support. Eur Respir J 2000;15:649-55.
26. Tantucci C, Duguet A, Similowski T, et al. Effect of salbutamol on dynamic hyperinflation in chronic obstructive pulmonary disease patients. Eur Respir J 1998;12:799-804.
27. Boni E, Corda L, Franchini D, et al. Volume effect and exertional dyspnoea after bronchodilator in patients with COPD with and without expiratory flow limitation at rest. Thorax 2002;57:528-32.
28. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl I):i1-232.